Komori
Financial results presentation4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice of the publication of an article, “Logmi Finance earnings briefing transcript,” for the fiscal year ending March 2026

The content of the financial results briefing for the fiscal year ending March 2026 was published as a Logmi Finance transcript article on 20 May 2026. The financial results presentation materials were disclosed separately on the company's IR website and through TDnet.

Worth reading
56In focus
Scored from 1 of 6 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Contents of this document

Fiscal year ending March 20261 item taken from the company’s own explanation
What the company explained in this material
New initiatives
  • Publication of the Logmi Finance transcript article on the financial results briefing for the fiscal year ending March 2026
Contents of this document
ItemDetails
Fiscal Period CoveredFiscal year ending March 2026
New initiativesPublication of the Logmi Finance transcript article on the financial results briefing for the fiscal year ending March 2026
Items this document does not state (29)
Document typeNet SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To publish the content of the financial results briefing and provide investors with more opportunities to understand the company.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the publication of an article, “Logmi Finance earnings briefing transcript,” for the fiscal year ending March 2026 | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori